company background image
GYRE logo

Gyre Therapeutics NasdaqCM:GYRE Stock Report

Last Price

US$10.02

Market Cap

US$943.2m

7D

1.0%

1Y

-53.0%

Updated

11 Dec, 2024

Data

Company Financials

Gyre Therapeutics, Inc.

NasdaqCM:GYRE Stock Report

Market Cap: US$943.2m

GYRE Stock Overview

A pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. More details

GYRE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Gyre Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Gyre Therapeutics
Historical stock prices
Current Share PriceUS$10.02
52 Week HighUS$30.40
52 Week LowUS$8.26
Beta0
1 Month Change-40.36%
3 Month Change-27.02%
1 Year Change-53.05%
3 Year Changen/a
5 Year Changen/a
Change since IPO48.89%

Recent News & Updates

Recent updates

A Look At The Fair Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Jun 27
A Look At The Fair Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Shareholder Returns

GYREUS BiotechsUS Market
7D1.0%-0.8%-0.2%
1Y-53.0%6.0%28.8%

Return vs Industry: GYRE underperformed the US Biotechs industry which returned 10.5% over the past year.

Return vs Market: GYRE underperformed the US Market which returned 30.1% over the past year.

Price Volatility

Is GYRE's price volatile compared to industry and market?
GYRE volatility
GYRE Average Weekly Movement10.0%
Biotechs Industry Average Movement10.3%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: GYRE has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: GYRE's weekly volatility has decreased from 16% to 10% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2002593Han Yingwww.gyretx.com

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease. The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.

Gyre Therapeutics, Inc. Fundamentals Summary

How do Gyre Therapeutics's earnings and revenue compare to its market cap?
GYRE fundamental statistics
Market capUS$943.19m
Earnings (TTM)-US$88.82m
Revenue (TTM)US$105.03m

8.2x

P/S Ratio

-9.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GYRE income statement (TTM)
RevenueUS$105.03m
Cost of RevenueUS$3.96m
Gross ProfitUS$101.08m
Other ExpensesUS$189.90m
Earnings-US$88.82m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.03
Gross Margin96.23%
Net Profit Margin-84.57%
Debt/Equity Ratio0%

How did GYRE perform over the long term?

See historical performance and comparison